Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025
Continuous Kidney Replacement Therapy and Outcomes of Severe Coronavirus Disease 2019 Treated With Extracorporeal Membrane Oxygenation.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Izutani Yoshito, Kawano Yasumasa, Fujita Akihiro, Morimoto Shinichi, Muranishi Kentaro, Hoshino Kota, Maruyama Junichi, Nakashio Maiko, Noake Junta, Hatomoto Hiroki, Yamasaki Shintaro, Yamauchi Kazuya, Hamaguchi Jun, Bunya Naofumi, Nakayama Ryuichi, Shimizu Keiki, Nakamura Yoshihiko
Аннотация
INTRODUCTION: Although continuous kidney replacement therapy (CKRT) for acute kidney injury (AKI) management is common, its effect on the outcomes of patients treated with extracorporeal membrane oxygenation (ECMO) for severe coronavirus disease 2019 (COVID-19) remains unclear. Therefore, we aimed to investigate the impact of CKRT on the outcomes of these patients.
METHODS: Using a database of patients with severe COVID-19 who required venovenous ECMO across three centers in Japan, we assessed demographics, clinical parameters, and in-hospital mortality rates from January 2020 to December 2021.
RESULTS: Data of 122 patients treated with ECMO for COVID-19 were analyzed. Forty-five patients required CKRT; the in-hospital mortality rate was 28.7%. Multivariate analysis showed age and CKRT were independent risk factors for in-hospital mortality. The in-hospital mortality rate was significantly higher in the CKRT group.
CONCLUSION: CKRT was associated with significantly high in-hospital mortality in patients treated with ECMO for severe COVID-19.
METHODS: Using a database of patients with severe COVID-19 who required venovenous ECMO across three centers in Japan, we assessed demographics, clinical parameters, and in-hospital mortality rates from January 2020 to December 2021.
RESULTS: Data of 122 patients treated with ECMO for COVID-19 were analyzed. Forty-five patients required CKRT; the in-hospital mortality rate was 28.7%. Multivariate analysis showed age and CKRT were independent risk factors for in-hospital mortality. The in-hospital mortality rate was significantly higher in the CKRT group.
CONCLUSION: CKRT was associated with significantly high in-hospital mortality in patients treated with ECMO for severe COVID-19.